Prof. Helena Kelly is the Head of the School of Pharmacy & Biomolecular Sciences at RCSI, reflecting her strong research and educational leadership profile. Her academic work spans drug discovery, delivery, and population health, aligned with RCSI’s strategic goal of innovating for a healthier future and the UN Sustainable Development Goals.
VisOxE for Radiotherapy Enhancement
Tumour hypoxia (lack of oxygen) is an important factor limiting the response to Radiotherapy, with up to 50%-60% of solid tumours being hypoxic. The aim of this project...
Lead: Prof. Helena Kelly, Prof. Stephen Maher
